Star Imaging and Path Lab Limited has upgraded its existing diagnostic centre located at Tilak Nagar, New Delhi, with the installation of a Toshiba Aquilion ONE 1184 Slice/Second CT Scanner. The installation significantly enhances the company's diagnostic capabilities by offering advanced imaging solutions with superior speed, accuracy, image quality, and patient comfort. This development was disclosed to the stock exchanges on June 08, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The upgradation reinforces the company's commitment to continuously strengthening its healthcare infrastructure, improving diagnostic outcomes, and providing high-quality medical services to patients. The new equipment is positioned as North India's first with 1184 slice/sec capability, featuring rapid acquisition of 0.27 sec and 16 cm whole-organ coverage.

Key Features of the Toshiba Aquilion ONE CT

The new scanner introduces several advanced features designed to improve clinical diagnostics:

• Advanced single-heartbeat cardiac imaging: Delivers enhanced coronary anatomy visualization and supports comprehensive evaluation of complex cardiac presentations.
• Advanced neuro imaging capabilities: Support acute assessment, perfusion analysis, and vascular evaluation when time matters most.
• Advanced oncology imaging: Enables detailed lesion evaluation, volumetric assessment for staging and follow-up, and extensive anatomical coverage in a single examination.
• Comprehensive diagnostic evaluation: Provides broad imaging support for complex presentations and reduces dependence on multiple investigations.

Star Imaging and Path Lab Limited is a diagnostic healthcare services provider with a presence across North India. The company offers an integrated portfolio of radiology, pathology, preventive healthcare, and advanced imaging services, supported by NABL & NABH-accredited facilities.

Star Imaging and Path Lab Limited has reported a 21% increase in net profit to ₹19.3 crore for the financial year ended March 31, 2026, up from ₹15.9 crore in the prior year. The Board of Directors approved the standalone and consolidated financial results during a meeting held on May 22, 2026. Following the announcement, the company made the audio recording of its earnings call, held on May 25, 2026, available for stakeholders.

Financial Performance

Revenue from operations for the full year stood at ₹88.5 crore, compared to ₹83.2 crore in the previous year. For the half year ended March 31, 2026, the net profit was recorded at ₹9.2 crore on total revenue of ₹43.3 crore. The earnings per share (EPS) for the full year was reported at ₹11.09 on a basic and diluted basis.

Operational Highlights

Star Imaging's EBITDA for FY26 stood at ₹33.2 crore, a 17% increase from the previous year, with an EBITDA margin of 37.5%. The company operates 24 diagnostic centers and continues to expand its footprint in Delhi, Uttar Pradesh, and Maharashtra. The investor presentation highlighted a reclassification of one business segment from B2C to B2B to reflect accurate operational data.

IPO Proceeds Utilization

The company disclosed the utilization of its Initial Public Offering (IPO) proceeds, which totaled ₹5,566.40 lakhs. As of March 31, 2026, the company had utilized ₹4,053.60 lakhs. The primary allocations included meeting working capital requirements (₹2,500.00 lakhs), loan repayment (₹1,200.00 lakhs), and the purchase of medical equipment (₹514.08 lakhs). The balance proceeds yet to be utilized amounted to ₹1,512.80 lakhs.

Auditor's Report

M/s. BHS & Co, Statutory Auditors of the company, issued an audit report with an unmodified opinion on the audited financial results for both standalone and consolidated statements. The report confirms that the financial results give a true and fair view of the company's financial performance in conformity with Indian Accounting Standards.

Future Outlook

Management expressed confidence in delivering 25%-30% growth in FY27, following regulatory delays that impacted execution in FY26. The company plans to expand its diagnostic centre footprint and deepen capabilities in molecular diagnostics and advanced imaging. Capital expenditure for FY27 is estimated between ₹20 crore and ₹25 crore, primarily for equipment purchase and construction.